Αρχική World News The Galleri multi-cancer blood test: what you need to know

The Galleri multi-cancer blood test: what you need to know

A blood test that has the potential to detect over 50 kinds of cancer is now being trialled in the NHS in England.

The Galleri blood test, developed by the company GRAIL, aims to detect cancers earlier by looking for abnormal DNA shed from cancer cells into the blood.

So far, the blood test has only been trialled on people who have already been diagnosed with cancer, but this study will see if it can spot cancer in people without symptoms.

There has been a lot of excitement about the Galleri test, and it’s obvious to see why, but that can sometimes make it difficult to understand the full picture.

Here’s what you need to know.

What’s the Galleri blood test and how does it work?

The Galleri test is a blood test that has the potential of detecting multiple types of cancer. It does this by looking for DNA found in the blood, called cell-free DNA (cfDNA), that’s shed by both tumour cells and healthy cells into the bloodstream.

In order to only pick up on cfDNA that indicates the presence of cancer, Galleri uses modern genetic sequencing technology and artificial intelligence to scan for patterns of chemical changes in the cfDNA that come from cancer cells but aren’t found in healthy cells.

Galleri is only available in the UK in research settings at the moment, because there are important questions that need answering before it’s known if it should be used more widely.

What do we know so far?

Results from studies into Galleri have so far been promising.

GRAIL reports that the test can detect 50 different types of cancer with a false positive rate of 0.5%. This means that in approximately 200 people tested, 1 person would be expected to receive a positive result when they do not have cancer.

So far, the blood test has only been trialled on people who have already been diagnosed with cancer. In this group, the test accurately detected cancer in 51.5% of people. This gives an indication of the test’s sensitivity. The Galleri test was able to correctly predict the location of the tumour 89% of the time, which is important for knowing which follow-up diagnostic tests the patient needs to confirm their diagnosis.

A key challenge that this type of test faces is the difficulty in detecting very small quantities of abnormal DNA circulating in the blood.

Because the amount of tumour-derived cfDNA tends to increase as a cancer becomes more advanced, these types of blood tests tend to be better at picking up later stage disease. Based on the results reported so far, the test is not currently that good at picking up stage 1 cancer, where the cancer is small and hasn’t spread to other parts of the body.

What’s more, the number of cancers that have been analysed, particularly for some rarer cancer types, has been very small.

The NHS trial is an opportunity to trial the test in a much larger sample, with longer follow up of patients not testing positive and a chance to answer some of the big questions and iron out some of these limitations.

What’s the NHS study looking at?

The NHS trial will focus on whether the Galleri test can accurately and reliably detect cancer in people who aren’t suspected as having cancer and if it can find cancer at earlier stages than would otherwise have been the case.

It’s being organised by GRAIL in partnership with NHS England and will be run by The Cancer Research UK and King’s College London Cancer Prevention Trials Unit, led by director Professor Peter Sasieni.

Initially, the trial will recruit 140,000 people aged 50 to 77 who will be identified through NHS records and invited to take part.

A crucial consideration is that the research gives information about how acceptable and effective the test is across our diverse population and the team are keen to ensure they recruit participants from different background and ethnicities.

Everyone who takes part in the trial will have annual blood tests for 2 years. Half will have their samples tested using Galleri, and half will have theirs stored for future analysis. Those in the intervention group who receive a positive Galleri blood test result will be referred for further investigations in the NHS.

The trial will see if the test can significantly reduce the number of cancer cases diagnosed late at stages 3 or 4, compared to those whose samples aren’t tested. It will also help identify the negative impacts of the test. This includes monitoring the number of people who test positive but don’t go on to be diagnosed with cancer and if any cancers are missed by false negatives.

Initial results from this study are expected to be released by 2023. If positive, the study will be expanded to involve around 1 million participants in 2024 and 2025. There will also be longer term follow up of the participants, to see if there were any differences in the number of people dying of cancer in the different groups.

Thinking of joining the trial?

Research is vital to making progress. But there’s a lot to consider when taking part in research, so we’d encourage anyone who receives an invitation to the GRAIL Galleri trial to read the information and decide what’s right for them.

If you do decide to take part, it’s really important that you still report any unusual changes in your health to a GP and consider invitations to NHS cancer screening as you would do normally.

This is because not everyone in the trial will have their blood samples analysed, and the test won’t identify everyone who has cancer.

You can find out more on the NHS Digital website

In a different study, 25,000 people with possible cancer symptoms will also be offered the test once they have been referred to hospital. People taking part in the study (SYMPLIFY) will have their diagnostic test(s) in the normal way, but will also give a blood sample and permission for the study team to check their health records later to see if they were diagnosed with cancer and what appointments and other tests they had.

At the end of the study, having tested the blood with the Galleri test, the team will understand more about how well it works in this group of people.

This will help them to design a trial where they can further explore if the test can be used to decide who needs rapid referral to look for a possible cancer and what diagnostic tests might be appropriate to use.

This might be particularly helpful when patients experience symptoms that could be linked to several different types of cancer.

One to watch

The Galleri blood test has encouraging initial data, and it’s great to see NHS England supporting research on this scale because there are many questions that need to be answered before it could be made available in the NHS, including how useful and effective it is and who it might be best to use it with and when.

It will take time to know if Galleri can make a difference and how it should best be used. And regardless of the results, one test alone is unlikely to get us to the point where all cancers are detected at an early stage. Galleri isn’t the only test of its kind in development – research into different ways of detecting cancer early range from blood tests to urine and even poo tests.

In the past year alone we have seen news of blood and urine tests to detect brain, bladder, ovarian and lung cancers, all at varying stages of development.

And tests like these are just one part of a wider picture of investment and action needed to increase the number of cancers detected earlier.

Other recent innovative approaches, such as Cytosponge, the ‘sponge-on-a-string’ to detect a condition that could lead to oesophageal cancer, and Colon Capsule Endoscopy, a disposable camera that’s small enough to swallow and powerful enough to help rule out bowel cancer, exemplify the huge potential of this research field.

These innovations must be supported by having enough NHS staff, infrastructure and kit to ensure that innovative tests can be made available to everyone who could benefit.

It’s early days for the GRAIL blood test. But it’s so exciting to see this research happening and we look forward to seeing more tests of promise being taken through to trials, pilots and implementation, to drive much-needed benefit for patients.

Harry

More on this topic

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...